Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. - Wikidata - wikimedia - TriplyDB

Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency.

Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency.

http://www.wikidata.org/entity/Q37313583

about

Purification of baculovirus vectors using heparin affinity chromatography.Delivery of large transgene cassettes by foamy virus vector.Production and Purification of Baculovirus for Gene Therapy Application.

P2860

Q37481526-A27F8B1F-1648-4AD0-95E5-4A4F9E272922 Q40083126-B157F7C5-C78E-420A-83D7-6C99FB0D66EA Q52717516-314C63FE-7531-4DA8-BAFD-9B7E5FB73CB5

P2860

Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency.

http://www.wikidata.org/entity/Q37313583

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Production and purification of ...... leukocyte adhesion deficiency.

@en

Production and purification of ...... leukocyte adhesion deficiency.

@nl

type

label

Production and purification of ...... leukocyte adhesion deficiency.

@en

Production and purification of ...... leukocyte adhesion deficiency.

@nl

prefLabel

Production and purification of ...... leukocyte adhesion deficiency.

@en

Production and purification of ...... leukocyte adhesion deficiency.

@nl

P1433

Q37313583-C5463020-DCC8-4CB5-BFD8-88E2E376CD90

P1476

Q37313583-7CB7527D-F969-4E50-9E75-3EF2F6315B35

P2093

Q37313583-053831DE-7A1A-41ED-8558-CF1489376378

Q37313583-26E59D1E-E49B-4CF6-8A5A-7AADA910F3BA

Q37313583-27433EFF-CA56-437D-B7E9-E37D849C9002

Q37313583-38F7C06B-DE4B-4DCC-9C0F-571EC0031741

Q37313583-3DFB7C61-E7AA-414B-9AE2-FBBA92AEE212

Q37313583-3F77B219-2577-4213-ABA1-801F6AE56AEC

Q37313583-43593F73-7DC1-4B29-B320-2BC33B1AA457

Q37313583-76CBD1A6-4BFB-4C41-8D80-5098DD23DDA6

Q37313583-93F266D7-A1A5-496A-9D74-534AE1AB20D5

Q37313583-96BBA146-576D-4A12-A0C7-8B310BB3C19A

P2860

Q37313583-00AB8E6C-E24A-42BF-A839-8B3A81AF38B3

Q37313583-0A8EE331-2348-4778-A474-F8874712D84C

Q37313583-0BBF10B6-8F91-4652-900E-BA052D2D71BB

Q37313583-15946EE2-FED9-4E2A-BB79-3452B6C6F543

Q37313583-185B45B3-B690-4B57-9553-1DD8F687C34E

Q37313583-362E33E6-63DD-4DE1-8A5E-68AE787697CA

Q37313583-391B1B5E-1320-47F1-AF91-88F449F8D41B

Q37313583-3CC85EDC-1AB2-402C-850D-3A20D7247680

Q37313583-3FD2E53D-D074-4893-BD6B-2277E3B8E460

Q37313583-40B2F914-3165-4263-A2F4-912CE35C7D78

P304

Q37313583-04E38937-D0BA-4FA0-B4BB-608C1142D2AF

P31

Q37313583-E9CA3312-6B20-4446-BAE3-4B130F33D491

P356

Q37313583-B3339ED4-F9BA-4542-AEA9-3638354901CE

P478

Q37313583-EBCD9D80-4BE2-436F-B75D-E2FA3E811512

P577

Q37313583-FFDA8CF3-7D46-416B-BE5B-2403B8F1BCD5

P5875

Q37313583-67373FCD-3C37-4468-BA4E-667399A5D9AE

P698

Q37313583-CA7FF079-8DFF-46A6-AC33-DD26F952D0C2

P921

Q37313583-14AFAB39-9B83-43C0-8551-B5CBC2754109

P932

Q37313583-595D61E3-77E5-4F81-A49A-FB551CB9278F

P356

P1433

Molecular Therapy. Methods & Clinical Development

P1476

Production and purification of ...... leukocyte adhesion deficiency.

@en

P2093

Andre Larochelle

http://www.w3.org/2001/XMLSchema#string

Archana Shrestha

http://www.w3.org/2001/XMLSchema#string

Carolyn Lutzko

http://www.w3.org/2001/XMLSchema#string

Danielle Lynn

http://www.w3.org/2001/XMLSchema#string

David W Russell

http://www.w3.org/2001/XMLSchema#string

Diana Nordling

http://www.w3.org/2001/XMLSchema#string

Johannes C M Van der Loo

http://www.w3.org/2001/XMLSchema#string

Kevin Link

http://www.w3.org/2001/XMLSchema#string

Md Nasimuzzaman

http://www.w3.org/2001/XMLSchema#string

Michele Beuerlein

http://www.w3.org/2001/XMLSchema#string

P2860

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection

Foamy virus vector integration sites in normal human cells

Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis.

Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.

Helper-free foamy virus vectors

Production of lentiviral vectors.

P304

16004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MTM.2016.4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

298731828

http://www.w3.org/2001/XMLSchema#string

P698

27722179

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

5052019

http://www.w3.org/2001/XMLSchema#string